Bausch & Lomb SVP, Controller, CAO Sold Shares Worth Over $2.2M

Bausch & Lomb's SVP, Controller, and CAO Frederick Munsch sold 112,015 shares at $20.48 each, totaling $2.29M. He now directly owns 45,831 shares, according to an SEC Form 4 filing.

Original reporting
Published Nov 2, 2026, 10:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 10:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bausch & Lomb SVP, Controller, CAO Sold Shares Worth Over $2.2M — source image
Decision brief

The 30-second read

$BHCNeutralLow
01

Why it matters

The insider sale is modest and typical for executive compensation planning; unlikely to trigger significant price movement.

02

Market read

The filing provides a data point for investors monitoring insider activity but offers limited trading impetus.

03

What to watch

Executive may be diversifying personal portfolio; no change to company fundamentals.

Relevance 5/10Novelty 5/10Timing: after-market filing

Background

Bausch Health Companies Inc. (BHC) disclosed an insider transaction via SEC Form 4.

Company-level read

Ticker impact

$BHCNeutralMedium confidence
Context

Form 4 filing shows SVP and CAO sold 112,015 shares for $2.29M, reducing his stake.

Expected impact

potential slight pressure as market prices in the insider sell

Evidence & confidence

Sale amount is under 1% of float; typical for diversification, unlikely to move price significantly.

Market effects

Minimal impact on healthcare sector; insider activity is routine.

US market only; no broader regional effect.

Low relevance globally.

Counterpoint

Sale could be a strategic reallocation rather than a negative signal.

Key entities

  • Munsch Frederick

    SVP, Controller and Chief Accounting Officer of Bausch Health Companies.

Related articles

$BHCMedAI 8/10

Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone

Bausch Health (BHC) rose 21% after reporting adjusted EPS of $1.77, beating estimates, and raising its full-year outlook. Core EBITDA, excluding Bausch + Lomb, exceeded $1 billion for the first time. Xifaxan's growth and debt reduction contributed to the results. The company also anticipates a Medicare price impact on Xifaxan in 2027. AbbVie (ABBV) and Teva (TEVA) face similar challenges with their drugs. BHC's forward P/E remains below its five-year average.

$BHCHighAI 8/10

Bausch Health Companies Inc (BHC) Q3 2026 Earnings Call Highlights: Adjusted EBITDA Tops

Bausch Health (BHC) reported Q3 2026 earnings, raising full-year guidance. Adjusted EBITDA exceeded $1B. CFO JJ Sharon noted a $100M+ impact from Xifaxan price adjustments. CEO Thomas Appio discussed Solta's growth and regulatory timelines. Salix revenue rose 16% to $831M, driven by Xifaxan. The company reduced debt by $521M and announced a $50M share repurchase program.